We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+10.19%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$10.2B
AUM Growth
+$2.04B
(+25%)
Cap. Flow
+$1.34B
Cap. Flow
% of AUM
13.16%
Top 10 Holdings %
Top 10 Hldgs %
16.92%
Holding
1,109
New
201
Increased
523
Reduced
236
Closed
122
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$57.2M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$52.3M |
| 3 |
Micron Technology
MU
|
+$46M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$45.6M |
| 5 |
Apple
AAPL
|
+$41.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$76.7M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$62.9M |
| 3 |
NVR
NVR
|
+$49.7M |
| 4 |
AZPN
ASPEN TECHNOLOGY INC
AZPN
|
+$37.5M |
| 5 |
DFS
Discover Financial Services
DFS
|
+$35.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.58% |
| 2 | Financials | 15.64% |
| 3 | Healthcare | 14.3% |
| 4 | Consumer Discretionary | 12.01% |
| 5 | Industrials | 9.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
JNCE
651
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $1.2M | 0.01% |
136,895
+53,729
| +65% | +$290K |
|
652
Seagate
STX
$181B
| $1.19M | 0.01% |
20,010
-2,090
| -9% | -$120K |
|
653
Genie Energy
GNE
$382M
| $1.19M | 0.01% |
+153,922
| New | +$1.21M |
|
|
BFX
654
DELISTED
BowFlex Inc.
BFX
| $1.19M | 0.01% |
679,337
+95,677
| +16% | +$149K |
|
|
ISEE
655
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $1.19M | 0.01% |
138,283
-25,199
| -15% | -$90K |
|
|
SEAC
656
DELISTED
Seachange International Inc
SEAC
| $1.18M | 0.01% |
14,101
+4,314
| +44% | +$293K |
|
|
FLG
657
Flagstar Bank National Association
FLG
$5.75B
| $1.18M | 0.01% |
+32,716
| New | +$1.21M |
|
|
GNMK
658
DELISTED
GenMark Diagnostics, Inc
GNMK
| $1.18M | 0.01% |
245,118
+164,491
| +204% | +$907K |
|
|
DZSI
659
DELISTED
DZS Inc. Common Stock
DZSI
| $1.18M | 0.01% |
+132,985
| New | +$1.05M |
|
660
Gen Digital
GEN
$16B
| $1.18M | 0.01% |
+46,126
| New | +$1.13M |
|
661
iShares Russell 2000 Growth ETF
IWO
$14.4B
| $1.17M | 0.01% |
5,480
| – | – |
|
|
PBPB
662
DELISTED
Potbelly
PBPB
| $1.17M | 0.01% |
278,101
+228,404
| +460% | +$997K |
|
|
CMRX
663
DELISTED
Chimerix, Inc.
CMRX
| $1.17M | 0.01% |
576,638
+114,135
| +25% | +$210K |
|
664
Axogen
AXGN
$2.17B
| $1.17M | 0.01% |
+65,401
| New | +$966K |
|
|
CURO
665
DELISTED
CURO Group Holdings Corp.
CURO
| $1.16M | 0.01% |
+95,565
| New | +$1.28M |
|
|
TPCO
666
DELISTED
Tribune Publishing Company Common Stock
TPCO
| $1.16M | 0.01% |
87,901
+20,426
| +30% | +$215K |
|
667
CEVA Inc
CEVA
$963M
| $1.15M | 0.01% |
42,719
| – | – |
|
668
Seres Therapeutics
MCRB
$48.8M
| $1.15M | 0.01% |
16,670
+8,813
| +112% | +$654K |
|
669
HNI Corp
HNI
$3.09B
| $1.15M | 0.01% |
+30,567
| New | +$1.17M |
|
670
Labcorp
LH
$24.4B
| $1.14M | 0.01% |
7,848
-10,520
| -57% | -$1.52M |
|
671
Blackbaud
BLKB
$1.58B
| $1.14M | 0.01% |
14,302
+8,402
| +142% | +$703K |
|
672
LiveRamp
RAMP
$2.3B
| $1.13M | 0.01% |
23,430
-16,270
| -41% | -$731K |
|
673
Financial Institutions
FISI
$803M
| $1.12M | 0.01% |
34,759
+6,075
| +21% | +$191K |
|
674
Puma Biotechnology
PBYI
$413M
| $1.1M | 0.01% |
126,175
+21,355
| +20% | +$177K |
|
|
SPPI
675
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $1.1M | 0.01% |
+301,874
| New | +$2.44M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q4 2019 Portfolio in Review
As of Q4 2019, Jacobs Levy Equity Management held 1,109 positions worth $10.2B, up 25% from $8.15B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $1.34B of net new capital in Q4 2019, opening 201 new positions and adding to 523 existing holdings. Its largest new stake was Athene Holding Ltd. Class A Common Shares: 551,505 shares worth $25.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Qualcomm, an estimated $76.7M trimmed.
- Jacobs Levy Equity Management's largest Q4 2019 buy was Athene Holding Ltd. Class A Common Shares: 551,505 shares worth $25.9M.
- Jacobs Levy Equity Management added most to AbbVie in Q4 2019, an estimated $57.2M increase.
- Jacobs Levy Equity Management's biggest Q4 2019 reduction was Qualcomm, cutting an estimated $76.7M.
- Jacobs Levy Equity Management fully exited NVR in Q4 2019, selling an estimated $49.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $10.2B portfolio in Q4 2019.
- Jacobs Levy Equity Management opened 201 new positions and closed 122 in Q4 2019.
- Jacobs Levy Equity Management's portfolio value rose 25% quarter-over-quarter to $10.2B.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2019, filed 14 Feb 2020.